22 January 2021: Original Paper
Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial
Hyung Duk Kim 1BEF , Ji-Yeun Chang 1CDE , Byung Ha Chung 1AB , Chan-Duck Kim 2B , Sang-Ho Lee 3B , Yeong Hoon Kim 4B , Chul Woo Yang 1ADG*DOI: 10.12659/AOT.927984
Ann Transplant 2021; 26:e927984
Table 5 Serious adverse events in ITT population.
| EVL group (n=38) | TAC group (n=39) | |
|---|---|---|
| Total events, n (%) | 13 (100.00) | 10 (100.00) |
| Diarrhea | 1 (7.69) | 0 (0.00) |
| Suspicious allograft rejection | 3 (23.08) | 0 (0.00) |
| Gastroenteritis | 1 (7.69) | 0 (0.00) |
| Herpes zoster | 0 (0.00) | 1 (10.00) |
| Influenza | 1 (7.69) | 0 (0.00) |
| Urinary tract infection | 6 (46.15) | 4 (40.00) |
| Varicella | 0 (0.00) | 1 (10.00) |
| Viral meningitis | 0 (0.00) | 1 (10.00) |
| Gastric adenoma | 0 (0.00) | 1 (10.00) |
| Ureterolithiasis | 0 (0.00) | 1 (10.00) |
| Bleeding time prolongation | 1 (7.69) | 0 (0.00) |
| Fibrocystic breast disease | 0 (0.00) | 1 (10.00) |
| Discrete variables are presented with n (%). | ||